Total Funding
68
40
Total FundingPost-IPO Equity raised
Growth Score
0 pts
Heat Score
7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
37509
Surrozen is a biopharmaceutical that focuses on unlocking the body’s regenerative power to treat injury and disease.
- Daniel Chao: Vice President and Head of Clinical DevelopmentPast Role: Visgenx, Scientific Co-Founder
- Claudia Janda: Co-Founder and Senior Scientist
About the Company
Surrozen is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with potential application across multiple disease areas, including diseases of the intestine, liver, retina,
cornea, lung, kidney, cochlea, skin, pancreas and central nervous system.
Women Founded
